Northern Arc Capital Fund Raise of ₹500 Cr

Northern Arc Capital Management Change

Northern Arc Capital reappointed Ms. Anuradha Rao as Non-Executive, Non-Independent Director as an additional director for one year from October 31, 2026, subject to shareholder approval. The filing is a Reg 30 senior director appointment disclosure.

Northern Arc Capital Board Meeting Date

Northern Arc Capital has scheduled its Board Meeting for November 3, 2026, to approve Q2 and H1 FY27 unaudited results. Trading window closes November 5, 2026.

Northern Arc Capital Other Announcement

The company filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Listing Regulations.

Northern Arc Capital Employee Stock Options

Northern Arc Capital Limited has allotted 3,000 equity shares of Rs. 10 each to employees upon exercise of stock options under its ESOP scheme.

Northern Arc Capital Employee Stock Options

Northern Arc Capital allotted 1,44,000 ESOP shares to option grantees under its 2016 plan. Paid-up equity capital increased to Rs. 161.81 Crore.

Northern Arc Capital Other Announcement

Northern Arc Capital Limited submitted its monthly Asset Liability Management (ALM) statement for July 2026 to the Reserve Bank of India, as mandated by regulatory requirements.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.